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Abstract
There is an ongoing debate regarding the efficacy of
glycaemic control in critically ill patients. Here we briefly
highlight the key function of elevated glucose in
critically ill patients, namely, to enable elevation of
aerobic glycolysis in rapidly dividing cells. In particular,
aerobic glycolysis provides metabolic intermediates
necessary for expansion of biomass in immune cells
and promotion of tissue repair. Furthermore, we
emphasise that insulin may inhibit autophagy, a cell
survival process used in the bulk degradation of
cellular debris and damaged organelles. These
observations provide a rational basis for tolerating
elevated glucose levels in certain critically ill patients.
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Introduction
The hyperglycaemia observed during immune activation
was initially seen as an adaptive response linked to the
normal stress response. This view was challenged by the
findings that insulin therapy in critically ill patients to
reduce glucose levels below 110 mg/dL (6.1 mmol) resulted
in a dramatic decrease in mortality [1]. Subsequently, the
hyperglycaemia observed during an infection has been
described as a defect of glucose homeostasis [2]—a mani-
festation of pathology that must be treated. A number of
observations also support this view. As an example, hyper-
glycaemia has consistently been associated with an adverse
outcome in patients with sepsis, irrespective of their dia-
betic status [3]. Furthermore, hyperglycaemia is not only
associated with activation of inflammatory responses, but
in fact has been found to be a causative agent behind the
development of certain pathologies. This is particularly
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well exemplified by literature on the consequence of
hyperglycaemia observed in diabetes. In diabetic patients,
continual hyperglycaemia can injure endothelial cells and
decrease the capillary bed density in various organs.
Mechanistically, hyperglycaemia can increase the forma-
tion of advanced glycation end products (AGE) when pro-
teins and lipids become glycated. This may promote a
number of detrimental consequences, particularly the
binding of AGE to the receptors for advanced glycation
end products (RAGE) on immune cells, which may illicit
an inflammatory response [4]. There is also evidence that
hyperglycaemia might cause mitochondrial damage. In
mice, prolonged exposure to an obesogenic diet resulted
in insulin resistance, followed by mitochondrial dysfunc-
tion associated with an increase in reactive oxygen species
production [5]. These changes were also observed when
diabetes was chemically induced (treated with streptozoto-
cin), suggesting that increased mitochondrial dysfunction
was a result of hyper-glycaemia/lipidaemia [5]. These
observations provide a mechanistic foundation by which
hyperglycaemia adversely affects critically ill patients, thus
providing a rational basis for treating hyperglycaemia in
critically ill patients.
However, a number of subsequent studies have failed to
show the benefits of glycaemic control [6–11], and some
have even found adverse effects associated with strict
glycaemic control [12]. The Surviving Sepsis Campaign
now recommends targeting blood glucose levels below
180 mg/dL instead of the previous tight (<110 mg/dL)
glycaemic levels [13]. Hence, the targeting of glucose
levels remains a topic that solicits intense debate [14–16].
What is evident, however, is that some patients do seem
to benefit from controlled glucose levels, whereas others
obviously do not.
A growing understanding of the metabolic needs of
activated immune cells provides a new view on the
effect of glycaemic control. Here we briefly review
both established work as well as recently emerging
insights into the metabolism of activated immune cells. It
is argued that glycaemic control might in effect exert an
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immune-suppressive effect, which may diminish the host’s
ability to launch a competent immune response. In fact,
the anti-inflammatory effects of insulin might mediate
some of the beneficial effects of glycaemic control,
suggesting that the metabolism of immune cells may
represent novel targets for anti-inflammatory interven-
tions. Secondly, insulin itself may adversely affect patient
outcome by inhibiting autophagy, a generic cell survival
response. From these considerations, it is clear that
glycaemic control may not represent optimum support for
all patients.
The metabolic sweet spot
Lactic acidosis has been ascribed to systemic anaerobic
conditions resulting from hypoperfusion manifesting as
tissue hypoxia. Indeed, sepsis is often associated with a
decrease in blood pressure (in severe cases manifesting
as septic shock) which could leave tissue hypoxic. How-
ever, evidence emerged that lactic acid build-up poorly
correlates with tissue hypoxia. It has been shown that
sepsis does not compromise oxygen delivery compared
to normal individuals [17]. Indeed, therapies aimed at
increasing oxygenation failed to improve clinical parame-
ters [18, 19]. These observations suggest that lactate build-
up is not solely dependent on tissue hypoxia [18, 19].
Other factors may include mitochondrial dysfunction
resulting from severe inflammation [20]. In addition, an
increase in lactate production by normal cells may also
contribute. Indeed, numerous cells make use of ‘aerobic
glycolysis’—the lactic acid fermentation of sugar despite
the abundance of oxygen. Vascular endothelium cells, des-
pite being in direct contact with oxygenated blood, pre-
sumably spare the oxygen supply on route for intended
tissue [21]. Cancer cells also exhibit an increase in glycoly-
sis despite the presence of oxygen—a phenomena referred
to as the ‘Warburg effect’ (named after Otto Warburg
who first described aerobic glycolysis in cancerous cells).
Aerobic glycolysis is not unique to proliferating cancer
cells, but is also a normal metabolic strategy enacted by
various rapidly dividing cells [22], including immune cells
[23]. Thus, an increase in aerobic glycolysis conducted by
activated immune cells likely contributes to the increase
in lactic acid build up through glycolytic activity in other
tissues, as well as a decrease in lactic acid clearance.
Yet, anaerobic glycolysis is highly inefficient: whereas
oxidative respiration yields 32 moles of ATP for each
mole of glucose fully oxidised, glycolysis only produces 2
moles of ATP. This then raises the question why the
immune system would make use of such a seemingly
ineffective system. One key benefit of making use of
aerobic glycolysis relates to energy production: though
the efficiency of ATP might be lower for aerobic glycoly-
sis compared to oxidative phosphorylation, the rate at
which ATP can be produced is much higher (i.e. more
ATP can be produced by glycolysis than oxidative phos-
phorylation in a given time unit) [24]. This would
suggest that elevated glycolysis in immune cells might
represent a metabolic strategy to rapidly increase cellular
ATP levels.
Energy production is not the only endpoint of aerobic
glycolysis in rapidly dividing cells. Indeed, another func-
tion of glycolysis is to provide metabolic intermediates
used in other biosynthetic pathways, such as for the
synthesis of lipids and nucleotides [22]. This also explains
why, in several cancer types, the contribution of glycolysis
to ATP production is marginal despite high glucose con-
sumption [25]. The application of aerobic glycolysis is
now also understood to play a pivotal role in the activated
immune cells of both the innate and adaptive immune
systems [26, 27]. As an example, activated monocytes rap-
idly increase the biosynthesis of fatty acids [28]. Interest-
ingly, following inhibition of fatty acid synthesis with RNA
interference, markers of macrophage differentiation were
decreased [28], indicating the reliance of differentiation on
metabolism. Here, glycolysis can be indispensable in pro-
viding the metabolic intermediates (such as acyl-CoA)
which can be used for lipid synthesis [22]. The use of
glucose for biosynthetic processes is similarly important in
cells of the adaptive immune system. As an example, upon
activation of a corresponding antigen, B cells rapidly
upregulate glucose uptake and glycolysis [29]. Moreover,
upregulation of the pentose phosphate pathway (PPP)
prior to cells entering the S phase was also observed. This
observation suggests that glucose might be shifted towards
biosynthetic pathways, since the PPP is also implemented
to provide metabolic intermediates [29].
Taken together, it is clear that glucose plays a central
role in the functioning of activated immune cells. Glucose
is important for both energy production and maintaining
biosynthetic activities associated with the rapid expansion
of immune cells and the production of immune modula-
tors/effectors during an infection. This also suggests that
hampering glucose supply would likely adversely affect
immune cell function.
Addressing the immunological needs:
hyperglycaemia
It is thus pivotal that immune cells receive adequate
amounts of glucose. Indeed, energy production by glycoly-
sis can only out-perform oxidative phosphorylation under
conditions of high glucose uptake [30]. Similarly, low glu-
cose levels are likely to compromise cellular biosynthetic
capacities. In this regard, a number of physiological adap-
tations exist to augment the glucose supply chain. Firstly,
activated immune cells rapidly upregulate the expression
of glucose transporters [31], thus enhancing the rate at
which glucose is imported. Interestingly, it has also been
noted that insulin plays an important role in T cells, since
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T cells lacking insulin receptors exhibit a dramatically
reduced glycolytic capacity [32]. This is surprising since
insulin levels are usually normal or slightly suppressed
during sepsis [33]. Regardless, glucose transporters follow
Michaelis–Menten kinetics, which implies that substrate
concentration (i.e. serum glucose levels) will influence the
rate at which glucose is transported into cells.
Serum glucose levels are elevated through a range of
physiological mechanisms. Various inflammatory media-
tors, such as Il-1b and TNF [34], Il-6 [35], as well as
type I and II interferons [36], induce insulin resistance.
In addition, evidence from mouse models suggests that a
decrease in blood flow to muscle might also contribute
to the lower glucose consumption in response to a lipo-
polysaccharide challenge [37]. However, gluconeogenesis
in the liver is a major contributing factor towards the
development of hyperglycaemia [2]. In fact, an increase
in nitrogen secretion reflects the increase in basal meta-
bolic rate (Fig. 1), as the carbon skeleton of amino acids
is used to produce glucose, which in turn fuels the
elevated metabolic state. Mechanistically, inflammatory
cytokines such as Il-6 increase the secretion of glucagon
by acting both on the central nervous system as well as
directly on islets cells [38]. Taken together, these responses
demonstrate the physiological adaptation to the unique
metabolic needs of immune cells during an infection, and
that altered glucose metabolism during an infection does
not represent a ‘dysregulation’ but a tailored response
geared towards the mobilisation of an effective immune
response.
These arguments suggest that hyperglycaemia is in ser-
vice of promoting and sustaining a competent immune
response. However, this does not mean that an immune
response is necessarily adaptive or desirable. Strict gly-
caemic control might exert beneficial effects by actually
impeding immune function. This might explain why
certain patients do benefit from insulin therapy. It is worth
noting that the Leuven study was predominantly in
patients that were assigned to an ICU after cardiac surgery
[1]. In the context of such sterile intervention, attenuating
immune function by glycaemic control might be beneficial
in avoiding unnecessary inflammation. In contrast, inhibit-
ing immune function in the context of an infection could
be disastrous.
Insulin and autophagy
Insulin, independent of altering glucose levels, may also
have unanticipated adverse effects. It has long been
noted that an anabolic hormone such as insulin can
inhibit the catabolic process of autophagy [39]. In fact,
evidence suggests that critically ill patients not only
exhibit traits of autophagic insufficiency, but that these
effects can be exacerbated by insulin therapy: hepato-
cytes from critically ill patients receiving insulin as part
of glucose control exhibited an 80% greater reduction in
autophagic vacuole formation compared to critically ill
patients receiving standard therapy [40]. Such an inhib-
ition of autophagy may have several adverse effects since
autophagy plays a pivotal role in both host defence as
well as cell survival [41]. In host defence, autophagy
plays a key function in the processing of epitopes to be
loaded on both MHC I and II, targeting intracellular
bacteria for autophagy degradation (referred to as xeno-
phagy). Furthermore, vesicles used for viral replication are
also degraded via autophagy. These processes are opera-
tive not only in immune cells, but also in non-immune
cells, highlighting the potential role of maintaining ele-
vated levels of autophagy during an infection [41].
Autophagy may also play a key role in surviving the
adverse conditions faced in a clinical setting, including
the removal of damaged or misfolded proteins (aggre-
phagy) as well as damaged mitochondria (mitophagy) or
the clearance of noxious factors such as bacteria and
endotoxins by the liver [41]. As an example, critically ill
patients demonstrate mitochondrial dysfunction with a
concomitant decrease in antioxidant capacity [42]. It is
very likely that damaged mitochondria result in an
increased formation of radicals, which in turn results in
decreased antioxidant capacity. Here, autophagy plays a
pivotal role in targeting damaged mitochondria for
Fig. 1 Activation of an immune response is associated with an increase in metabolic turnover a sustained by increased protein catabolism (b).
Redrawn with modification from [48]
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degradation [43]. The key role played by autophagy thus
also raises concerns regarding the role of insulin in
controlling hypoglycaemia while similarly also inhibiting
autophagy. In this study, however, patients were in a fed
state, which represents a confounding factor since feed-
ing may suppress autophagy.
Glycaemic control: novel therapeutic strategies
Activation of an inflammatory response is often accom-
panied by a decrease in appetite. Yet, despite a decrease in
nutrients, rapid expansion of the immune system, as well
as the synthesis of immune effectors, must be sustained.
In this regard, catabolism in peripheral tissue is directed
at maintaining anabolism of the immune system. Here we
have argued not merely that hyperglycaemia during
immune activation represents an evolutionarily conserved
response, but have, in fact, pointed out the reason why
elevated glucose levels may in fact play an important
function during an infection. However, the manner in
which metabolic alteration during an inflammatory
insult promotes immune function remains to be for-
mally investigated.
There is also a need to establish safe tolerable levels of
glycaemic control as extreme levels of hyperglycaemia
can, in fact, have a negative impact on immune function.
In a rabbit model of critical illness, maintaining glucoses
levels at 13.8–16.6 mmol/L and 13.875–19.425 mmol/L
adversely affected innate immune cell activity [44, 45].
Similarly, an increase in glucose levels might be adaptive
in the short term, but may exert negative effects (e.g.
mitochondrial dysfunction [5]) in a chronic setting. This
would suggest that glycaemic control might be beneficial
in managing a protracted state. A key question remains
whether glycaemic control might represent a strategy for
attenuating unwanted immune activation. In this regard,
insulin therapy is able to attenuate inflammation dramat-
ically [46]. If such an immune-suppressive effect is indeed
mediated by starving immune cells of glucose, it raises the
intriguing possibility that novel anti-inflammatory therap-
ies might be developed through targeting of immune cell
metabolism. As an example, one meta-analysis [47] has
failed to demonstrate any benefit of glycaemic control in
patients with sepsis, though a benefit was observed in
other ICU settings. This does not, however, indicate
that insulin therapy may not have beneficial effects in
sepsis. In this regard, insulin therapy may attenuate a
life-threatening inflammatory response. There is thus
a need to identify individuals who may best benefit
from glycaemic control.
Emerging evidence suggests a key role for autophagy
within a clinical context. However, more studies are
required to investigate the effect of insulin therapy on
autophagy. In the study by Vanhorebeek [40] critically ill
patients were in a fed state, which would attenuate
autophagy, thus representing a confounding factor. Also, if
lowering glucose levels prevents cellular damaged caused
by elevated glucose levels, it might mitigate the need for
higher autophagy. In addition, since autophagy is activated
in response to energy stress, it is also possible that hyper-
glycaemia might attenuate autophagy. Given the potential
role of autophagy, establishing the effect of glycaemic
control could be of great clinical value. More research is
urgently needed to provide a complete picture of the effect
exerted by intensive insulin therapy on autophagy.
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